HPV vaccination in HIV infection

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• Individuals with Human Immunodeficiency Virus (HIV) have an elevated risk of Human Papillomavirus (HPV) infection, disease, and associated cancers compared to HIV-negative individuals.
• Immune responses to vaccinations in people with HIV are often suboptimal, even with Antiretroviral Therapy (ART), remaining lower and declining faster than in HIV-negative individuals.

Purpose of the Study:

• To evaluate the immunogenicity and efficacy of HPV vaccines in individuals living with HIV.
• To explore potential improvements in HPV vaccine strategies for the HIV-positive population.

Main Methods:

• Review of existing studies on HPV vaccine immunogenicity and efficacy in HIV-positive populations.
• Comparison of different HPV vaccine formulations and dosing regimens.
• Analysis of immune responses to HPV vaccination in HIV-positive individuals.

Main Results:

• Evidence for HPV vaccine immunogenicity in HIV-positive individuals is reasonable, but efficacy data are inconsistent.
• Studies using Gardasil 4 (G4) have shown no effect or reduced effectiveness in HIV-positive men who have sex with men, women, and adolescents.
• Cervarix demonstrated superior immunogenicity compared to G4 in some studies.
• Hepatitis B vaccine studies suggest increased doses, higher vaccine concentration, or TLR agonist adjuvants enhance immunogenicity in HIV-positive individuals.

Conclusions:

• Optimal HPV vaccination regimens for individuals with HIV require further investigation.
• Additional clinical trials are needed to determine the most effective HPV vaccine strategies for people living with HIV.